Skip to main navigation
Skip to Content
logo
  • Overview
  • Stock Information
    • Stock Quote and Chart
    • Historical Price Lookup
    • IRS Form 8937
  • SEC Filings
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
    • Investor FAQs
  • Company
    • Press Releases
    • Events & Presentations
    • Pipeline
  • Contact Us
  • ImmunityBio.com

Press Releases

Press Releases

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
Jan 15, 2025
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
Jan 15, 2025
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
Jan 06, 2025

IR Tools

Print Page
RSS Feeds
Email Alerts
logo
© 2025 ImmunityBio, Inc. All Rights Reserved.
A member of the NantWorks ecosystem of companies

'ImmunityBio', 'ImmunityBio Care', 'Anktiva', 'ThAnktiva', 'haNK', 'taNK', 'ceNK', 'NK-92', 'Nant Cancer Vaccine', 'NANT 001', 'NANT XL', 'NANT 001 and Design', 'QUILT', 'Outsmart Your Disease', 'Smart Therapies for Difficult Diseases', 'Nantkwest', 'VivaBioCell', and 'Infacell' are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

NantKwest

Visit ImmunityBio.com

Social icons